Pfiz­er hits stum­bling block on Her­ceptin ri­val, but wins 'break­through' sta­tus on MenB vac­cine

This morn­ing’s news is a mixed bag for Pfiz­er $PFE, which re­port­ed up­dates on two dif­fer­ent pipeline drugs first thing Mon­day. One pro­gram saw a pos­i­tive de­vel­op­ment, while the oth­er was slapped with a set­back.

Let’s start with the bad news. The phar­ma gi­ant said reg­u­la­tors have re­ject­ed its trastuzum­ab biosim­i­lar, which was in­tend­ed as a cheap­er ver­sion of Roche’s can­cer drug Her­ceptin. Pfiz­er pla­cat­ed in­vestors by point­ing out that the FDA asked for more tech­ni­cal in­for­ma­tion to sup­port the ap­pli­ca­tion, not for safe­ty or clin­i­cal da­ta in­for­ma­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.